Angel Broking recommends `Buy’ on Aurobindo Pharmaceuticals. The broking firm has predicted that the stock may reach a price target of Rs 210 soon. It has mentioned in the recent report of the broking firm dated Feb. 25, 2011. Aurobindo Pharma (APL) has announced that it has received an import alert for the detention of products from its Cephalosporin facility (Unit VI).

The USFDA has imposed this import alert on Aurobindo Pharma (APL). Its Cephalosporin facility is located in Andhra Pradesh, India.

This unit of APL was audited by USFDA in the month of December last year. Later, the company had sent the compliance report to USFDA and these issues were under review of the audit team.

But now it has been informed that the USFDA has imposed an import alert to the company in its official website. It has also been mentioned over there that Unit IV of the company will also get the import alert along with Unit VI.

The broking house has also informed that the stock has corrected to its optimum level. So the investors can buy the stock with a target price of Rs 210.